Ovarian cancer+1
Not recruitingStudy of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy
Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy
- Disease:Ovarian cancerOvarian cancer recurrent
- Substances:MPS-102MPS-103+9
Belgium- Participants:18–64 years · 65+ years
- Substances:MPS-102
- Sponsor:Asso De Recherche Cancers Gynecologiques











